Patents Assigned to SciFluor Life Sciences, Inc.
  • Method of making tetrahydronaphthyridinyl nonanoic acid compounds
    Patent number: 10752625
    Abstract: The present application relates to methods of preparing a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 25, 2020
    Assignee: SciFluor Life Sciences, Inc.
    Inventor: Takeru Furuya
  • Fluorinated 4-(substituted amino)phenyl carbamate derivatives
    Patent number: 10676437
    Abstract: The application relates to 4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 9, 2020
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Takeru Furuya, Ben C. Askew, D. Scott Edwards
  • Fused imidazole derivatives as IDO/TDO inhibitors
    Patent number: 10308647
    Abstract: The present application relates to compounds and methods for the modulation (e.g., inhibition) of the enzyme indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase (IDO/TDO), and methods of treating diseases and disorders in which IDO/TDO plays a role.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: June 4, 2019
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Takeru Furuya
  • Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
    Patent number: 10301307
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: May 28, 2019
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Takeru Furuya
  • Method of making tetrahydronaphthyridinyl nonanoic acid compounds
    Patent number: 10253025
    Abstract: The present application relates to methods of preparing a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 9, 2019
    Assignee: SciFluor Life Sciences, Inc.
    Inventor: Takeru Furuya
  • Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
    Patent number: 10155758
    Abstract: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: December 18, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan
  • Nonanoic and decanoic acid derivatives and uses thereof
    Patent number: 10118929
    Abstract: The present disclosure relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present disclosure also relates to pharmaceutical compositions containing the fluorinated compounds of the disclosure, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 6, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Takeru Furuya, Ben C. Askew
  • Fluorinated integrin antagonists
    Patent number: 10106537
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 23, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Fluorinated benzofuran derivatives
    Patent number: 9895340
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 20, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
    Patent number: 9802933
    Abstract: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: October 31, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan
  • Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
    Patent number: 9790222
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: October 17, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Takeru Furuya
  • Fluorinated integrin antagonists
    Patent number: 9717729
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 1, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
    Patent number: 9662331
    Abstract: The invention relates to novel quinazolinone compounds and their use as inhibitors of PI3 kinases, for example, PI3K?, for treating and/or preventing diseases, disorder, and conditions associated with modulating PI3 kinase activity. Novel 3 -aryl-2-((arylamino)methyl)quinazolin-4(3H)-one derivatives and pharmaceutically acceptable salts or solvates thereof and their use for the treatment or prevention of diseases, disorders, and conditions associated with the activity of one or more PI3 kinase, such as PI3K?, are disclosed.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: May 30, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Takeru Furuya
  • Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds
    Patent number: 9624169
    Abstract: The application relates to novel compounds and their use in treating and preventing diseases and conditions mediated by modulation of voltage-gated sodium channels. Novel aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 18, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Takeru Furuya
  • Fluorinated benzofuran derivatives
    Patent number: 9624189
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 18, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
    Patent number: 9593114
    Abstract: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: March 14, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan
  • Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
    Patent number: 9572801
    Abstract: The present application relates to use of compounds of formula I for treating or preventing a fibrosis.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: February 21, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, D. Scott Edwards
  • Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
    Patent number: 9556114
    Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 31, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards, Ajay Purohit
  • Fluorinated integrin antagonists
    Patent number: 9518053
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: December 13, 2016
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-y1)-3-arylpropanoic acid derivatives
    Patent number: 9266884
    Abstract: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: February 23, 2016
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan